Real-world Study of Dedifferentiated Liposarcoma Patients in China
This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.
Dedifferentiated Liposarcoma
Cohort 1: Overall survival, Overall survival (OS) as an event for each patient in Cohort 1 will be defined as the date of death minus the index date or the start day of each line of therapy (LOT). For patients with no record of death, OS will be censored at the last activity date before the end of the study period., Up to 10 years
Cohort 1, Cohort 2: Survival after initial diagnosis, Survival after initial diagnosis for each patient will be defined as the date of death minus the date of initial diagnosis.

For patients with no record of death, survival after initial diagnosis will be censored at the last activity date before the end of the study period., Up to 10 years|Cohort 1, Cohort 2: First line (1L) of therapy by treatment type, Up to 10 years|Cohort 1, Cohort 2: Second line (2L) of therapy by treatment type, Up to 10 years|Cohort 1, Cohort 2: Third line (3L) of therapy by treatment type, Up to 10 years|Cohort 1, Cohort 2: Total number of treatment lines, Up to 10 years|Cohort 1, Cohort 2: Number of treatments with drugs classified as steroid therapy, Up to 10 years|Cohort 1, Cohort 2: Number of treatments with drugs classified as concurrent immunosuppressant therapy, Up to 10 years|Cohort 1, Cohort 2: Number of treatments with drugs classified as hormone replacement therapy, Up to 10 years
This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.